Osteocyte-specific deletion of Fgfr1 suppresses FGF23

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Xiao, Zhousheng ^a   Huang, Jinsong ^a   Cao, Li ^a   Liang, Yingjuan ^a   Han, Xiaobin ^a   Quarles, Leigh Darryl ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COMPLEMENTARY DNA; DENTIN MATRIX PROTEIN 1; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN; MESSENGER RNA; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; PHOSPHATIDYLINOSITOL 3 KINASE; SCLEROSTIN; DMP1 PROTEIN, MOUSE; FGFR1 PROTEIN, MOUSE; FIBROBLAST GROWTH FACTOR; SCLEROPROTEIN; VITAMIN D;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MINERALIZATION; BONE STRUCTURE; CELL SPECIFICITY; CONTROLLED STUDY; FEMALE; FGF23 GENE; FGFR1 GENE; GENE ACTIVATION; GENE DELETION; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HYPOPHOSPHATEMIA; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCYTE; OSTEOMALACIA; PHENOTYPE; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RICKETS; SIGNAL TRANSDUCTION; SUPPRESSOR GENE; VITAMIN D METABOLISM; ANIMAL; AUTOCRINE EFFECT; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; AUTOCRINE COMMUNICATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; HYPOPHOSPHATEMIA; MICE; MICE, KNOCKOUT; OSTEOCYTES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; VITAMIN D;

EID: 84905474545     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104154     Document Type: Article

References (83)

1. Stachowiak MK, Fang X, Myers JM, Dunham SM, Berezney R, et al. (2003) Integrative nuclear FGFR1 signaling (INFS) as a part of a universal "feed-forward-and-gate" signaling module that controls cell growth and differentiation. J Cell Biochem 90: 662-691. (Pubitemid 37392460)
2. Itoh N, Ornitz DM (2008) Functional evolutionary history of the mouse Fgf gene family. Dev Dyn 237: 18-27.
3. Itoh N (2010) Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 342: 1-11.
4. Yamashita T, Yoshioka M, Itoh N (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277: 494-498.
5. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, et al. (2003) Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426. (Pubitemid 37175262)
6. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, et al. (2001) Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505. (Pubitemid 32488266)
7. White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, et al. (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 2079-2086. (Pubitemid 33070451)
8. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, et al. (2008) {beta}Klotho Is Required for Fibroblast Growth Factor (FGF) 21 Signaling through FGF Receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22: 1006-1014. (Pubitemid 351482834)
9. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, et al. (2004) Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568. (Pubitemid 38542505)
10. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, et al. (2005) Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: F1088-1095. (Pubitemid 41447065)
11. Tomiyama K, Maeda R, Urakawa I, Yamazaki Y, Tanaka T, et al. (2010) Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc Natl Acad Sci U S A 107: 1666-1671.
12. Beckman MJ, Tadikonda P, Werner E, Prahl J, Yamada S, et al. (1996) Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 35: 8465-8472. (Pubitemid 26240500)
13. Hoenderop JG, Chon H, Gkika D, Bluyssen HA, Holstege FC, et al. (2004) Regulation of gene expression by dietary Ca2+ in kidneys of 25-hydroxyvitamin D3-1 alpha-hydroxylase knockout mice. Kidney Int 65: 531-539. (Pubitemid 38130647)
14. Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, et al. (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315. (Pubitemid 43673410)
15. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD (2008) FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19: 2342-2350.
16. Quarles LD (2011) The bone and beyond: 'Dem bones' are made for more than walking. Nat Med 17: 428-430.
17. David V, Dai B, Martin A, Huang J, Han X, et al. (2013) Calcium regulates FGF-23 expression in bone. Endocrinology 154: 4469-4482.
18. Quarles LD (2012) Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol 8: 276-286.
19. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, et al. (2005) 1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-1042. (Pubitemid 41740608)
20. Brown WW, Juppner H, Langman CB, Price H, Farrow EG, et al. (2009) Hypophosphatemia with Elevations in Serum Fibroblast Growth Factor 23 in a Child with Jansen's Metaphyseal Chondrodysplasia. J Clin Endocrinol Metab 94: 17-20.
21. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, et al. (2007) Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 18: 2683-2688. (Pubitemid 47531195)
22. Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299: F882-889.
23. Sato T, Tominaga Y, Ueki T, Goto N, Matsuoka S, et al. (2004) Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44: 481-487. (Pubitemid 39164625)
24. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774. (Pubitemid 44949607)
25. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, et al. (1997) Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51. (Pubitemid 27494749)
26. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, et al. (2004) Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct 29: 91-99. (Pubitemid 40260033)
27. Samadfam R, Richard C, Nguyen-Yamamoto L, Bolivar I, Goltzman D (2009) Bone formation regulates circulating concentrations of fibroblast growth factor 23. Endocrinology 150: 4835-4845.
28. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, et al. (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008. (Pubitemid 350224109)
29. Martin A, Liu S, David V, Li H, Karydis A, et al. (2011) Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J 25: 2551-2562.
30. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, et al. (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315. (Pubitemid 44646294)
31. Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, et al. (2008) Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118: 722-734. (Pubitemid 351206560)
32. Lorenz-Depiereux B, Schnabel D, Tiosano D, Hausler G, Strom TM (2010) Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 86: 267-272.
33. Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, et al. (2010) Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86: 273-278.
34. Martin A, David V, Quarles LD (2012) Regulation and Function of the FGF23/Klotho Endocrine Pathways. Physiol Rev 92: 131-155.
35. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, et al. (2005) Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76: 361-367. (Pubitemid 40129563)
36. Stevens DA, Harvey CB, Scott AJ, O'Shea PJ, Barnard JC, et al. (2003) Thyroid hormone activates fibroblast growth factor receptor-1 in bone. Mol Endocrinol 17: 1751-1766. (Pubitemid 37072292)
37. Xiao L, Esliger A, Hurley MM (2013) Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro. J Bone Miner Res 28: 35-45.
38. Xiao L, Naganawa T, Lorenzo J, Carpenter TO, Coffin JD, et al. (2010) Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO. J Biol Chem 285: 2834-2846.
39. Liu S, Tang W, Fang J, Ren J, Li H, et al. (2009) Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol 23: 1505-1518.
40. Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, et al. (2011) FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone. J Bone Miner Res 26: 2486-2497.
41. Wohrle S, Henninger C, Bonny O, Thuery A, Beluch N, et al. (2013) Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J Bone Miner Res 28: 899-911.
42. Wu AL, Feng B, Chen MZ, Kolumam G, Zavala-Solorio J, et al. (2013) Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS One 8: e57322.
43. Lu Y, Xie Y, Zhang S, Dusevich V, Bonewald LF, et al. (2007) DMP1-targeted Cre expression in odontoblasts and osteocytes. J Dent Res 86: 320-325.
44. Xiao Z, Dallas M, Qiu N, Nicolella D, Cao L, et al. (2011) Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice. FASEB J 25: 2418-2432.
45. Powell WF, Jr., Barry KJ, Tulum I, Kobayashi T, Harris SE, et al. (2011) Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J Endocrinol 209: 21-32.
46. Kim SW, Pajevic PD, Selig M, Barry KJ, Yang JY, et al. (2012) Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. J Bone Miner Res 27: 2075-2084.
47. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, et al. (2006) Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38-49. (Pubitemid 44035308)
48. Xiao ZS, Hjelmeland AB, Quarles LD (2004) Selective deficiency of the "bone-related" Runx2-II unexpectedly preserves osteoblast-mediated skeletogenesis. J Biol Chem 279: 20307-20313. (Pubitemid 38623476)
49. Zhang S, Xiao Z, Luo J, He N, Mahlios J, et al. (2009) Dose-dependent effects of Runx2 on bone development. J Bone Miner Res 24: 1889-1904.
50. Martin A, David V, Vico L, Thomas T (2008) Impaired energetic metabolism after central leptin signaling leads to massive appendicular bone loss in hindlimb-suspended rats. J Bone Miner Res 23: 2040-2047.
51. Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kasai S (1983) In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96: 191-198. (Pubitemid 13155577)
52. Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup RJ (1992) Distinct proliferative and differentiated stages of murine MC3T3-E1 cells in culture: an in vitro model of osteoblast development. J Bone Miner Res 7: 683-692.
53. Stachowiak EK, Fang X, Myers J, Dunham S, Stachowiak MK (2003) cAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1). J Neurochem 84: 1296-1312. (Pubitemid 36343596)
54. Wang Q, Green RP, Zhao G, Ornitz DM (2001) Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains. Development 128: 3867-3876. (Pubitemid 32998934)
55. Miyagawa K, Yamazaki M, Kawai M, Nishino J, Koshimizu T, et al. (2014) Dysregulated gene expression in the primary osteoblasts and osteocytes isolated from hypophosphatemic hyp mice. PLoS One 9: e93840.
56. Ichikawa S, Sorenson AH, Austin AM, Mackenzie DS, Fritz TA, et al. (2009) Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology 150: 2543-2550.
57. Ichikawa S, Austin AM, Gray AK, Econs MJ (2012) A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells. J Bone Miner Res 27: 453-460.
58. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, et al. (1998) Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol 275: E700-708.
59. Haupt LM, Murali S, Mun FK, Teplyuk N, Mei LF, et al. (2009) The heparan sulfate proteoglycan (HSPG) glypican-3 mediates commitment of MC3T3-E1 cells toward osteogenesis. J Cell Physiol 220: 780-791.
60. Shalhoub V, Ward SC, Sun B, Stevens J, Renshaw L, et al. (2011) Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int 89: 140-150.
61. Chlebova K, Bryja V, Dvorak P, Kozubik A, Wilcox WR, et al. (2009) High molecular weight FGF2: the biology of a nuclear growth factor. Cell Mol Life Sci 66: 225-235.
62. Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, et al. (2010) Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Res 70: 4868-4879.
63. Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 26: 229-238.
64. Ornitz DM, Marie PJ (2002) FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 16: 1446-1465. (Pubitemid 34686327)
65. Jacob AL, Smith C, Partanen J, Ornitz DM (2006) Fibroblast growth factor receptor 1 signaling in the osteo-chondrogenic cell lineage regulates sequential steps of osteoblast maturation. Dev Biol 296: 315-328. (Pubitemid 44189342)
66. Xu N, Qin Y, Reindollar RH, Tho SP, McDonough PG, et al. (2007) A mutation in the fibroblast growth factor receptor 1 gene causes fully penetrant normosmic isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92: 1155-1158. (Pubitemid 46465695)
67. Zhou YX, Xu X, Chen L, Li C, Brodie SG, et al. (2000) A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet 9: 2001-2008. (Pubitemid 30642665)
68. Senarath-Yapa K, Li S, Meyer NP, Longaker MT, Quarto N (2013) Integration of multiple signaling pathways determines differences in the osteogenic potential and tissue regeneration of neural crest-derived and mesoderm-derived calvarial bones. Int J Mol Sci 14: 5978-5997.
69. Liu S, Zhou J, Tang W, Menard R, Feng JQ, et al. (2008) Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab 295: E254-261.
70. Stubbs J, Liu S, Quarles LD (2007) Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 20: 302-308.
71. Aono Y, Yamazaki Y, Yasutake J, Kawata T, Hasegawa H, et al. (2009) Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res 24: 1879-1888.
72. Lim YH, Ovejero D, Sugarman JS, Deklotz CM, Maruri A, et al. (2014) Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet 23: 397-407.
73. Pendurthi UR, Rao LV, Williams JT, Idell S (1999) Regulation of tissue factor pathway inhibitor expression in smooth muscle cells. Blood 94: 579-586. (Pubitemid 29323872)
74. Freeman KW, Gangula RD, Welm BE, Ozen M, Foster BA, et al. (2003) Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. Cancer Res 63: 6237-6243. (Pubitemid 37255169)
75. Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, et al. (2012) Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 27: 38-46.
76. Yuan B, Feng JQ, Bowman S, Liu Y, Blank RD, et al. (2013) Hexa-D-arginine treatment increases 7B2*PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. J Bone Miner Res 28: 56-72.
77. Martin A, Liu S, David V, Li H, Karydis A, et al. (2011) Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. Faseb J.
78. Wohrle S, Bonny O, Beluch N, Gaulis S, Stamm C, et al. (2011) FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF23 signaling and regulating FGF23 expression in bone. J Bone Miner Res.
79. Yang W, Guo D, Harris MA, Cui Y, Gluhak-Heinrich J, et al. (2013) Bmp2 in osteoblasts of periosteum and trabecular bone links bone formation to vascularization and mesenchymal stem cells. J Cell Sci 126: 4085-4098.
80. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, et al. (1998) MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93: 411-422. (Pubitemid 28232085)
81. Yu K, Xu J, Liu Z, Sosic D, Shao J, et al. (2003) Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development 130: 3063-3074. (Pubitemid 36857252)
82. Li H, Martin A, David V, Quarles LD (2011) Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am J Physiol Endocrinol Metab 300: E508-517.
83. Gattineni J, Twombley K, Goetz R, Mohammadi M, Baum M (2011) Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4. Am J Physiol Renal Physiol 301: F371-377.